464 related articles for article (PubMed ID: 28424163)
1. Clinical significance of somatic mutation in unexplained blood cytopenia.
Malcovati L; Gallì A; Travaglino E; Ambaglio I; Rizzo E; Molteni E; Elena C; Ferretti VV; Catricalà S; Bono E; Todisco G; Bianchessi A; Rumi E; Zibellini S; Pietra D; Boveri E; Camaschella C; Toniolo D; Papaemmanuil E; Ogawa S; Cazzola M
Blood; 2017 Jun; 129(25):3371-3378. PubMed ID: 28424163
[TBL] [Abstract][Full Text] [Related]
2. Predicting cytopenias, progression, and survival in patients with clonal cytopenia of undetermined significance: a prospective cohort study.
Cargo C; Bernard E; Beinortas T; Bolton KL; Glover P; Warren H; Payne D; Ali R; Khan A; Short M; Van Hoppe S; Smith A; Taylor J; Evans P; Papaemmanuil E; Crouch S
Lancet Haematol; 2024 Jan; 11(1):e51-e61. PubMed ID: 38135373
[TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of clonal hematopoiesis in persons aged ≥80 years.
Rossi M; Meggendorfer M; Zampini M; Tettamanti M; Riva E; Travaglino E; Bersanelli M; Mandelli S; Antonella Galbussera A; Mosca E; Saba E; Chiereghin C; Manes N; Milanesi C; Ubezio M; Morabito L; Peano C; Soldà G; Asselta R; Duga S; Selmi C; De Santis M; Malik K; Maggioni G; Bicchieri M; Campagna A; Tentori CA; Russo A; Civilini E; Allavena P; Piazza R; Corrao G; Sala C; Termanini A; Giordano L; Detoma P; Malabaila A; Sala L; Rosso S; Zanetti R; Saitta C; Riva E; Condorelli G; Passamonti F; Santoro A; Sole F; Platzbecker U; Fenaux P; Bolli N; Castellani G; Kern W; Vassiliou GS; Haferlach T; Lucca U; Della Porta MG
Blood; 2021 Nov; 138(21):2093-2105. PubMed ID: 34125889
[TBL] [Abstract][Full Text] [Related]
4. Significance of myelodysplastic syndrome-associated somatic variants in the evaluation of patients with pancytopenia and idiopathic cytopenias of undetermined significance.
Fernandez-Pol S; Ma L; Ohgami RS; Arber DA
Mod Pathol; 2016 Sep; 29(9):996-1003. PubMed ID: 27255165
[TBL] [Abstract][Full Text] [Related]
5. Pedigree investigation, clinical characteristics, and prognosis analysis of haematological disease patients with germline TET2 mutation.
Wu X; Deng J; Zhang N; Liu X; Zheng X; Yan T; Ye W; Gong Y
BMC Cancer; 2022 Mar; 22(1):262. PubMed ID: 35279121
[TBL] [Abstract][Full Text] [Related]
6. The diagnostic utility of targeted gene panel sequencing in discriminating etiologies of cytopenia.
Zheng G; Chen P; Pallavajjalla A; Haley L; Gondek L; Dezern A; Ling H; De Marchi F; Lin MT; Gocke C
Am J Hematol; 2019 Oct; 94(10):1141-1148. PubMed ID: 31350794
[TBL] [Abstract][Full Text] [Related]
7. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
[TBL] [Abstract][Full Text] [Related]
8. Clinical and pathologic challenges of clonal cytopenia of undetermined significance.
Weinberg OK
Int J Lab Hematol; 2021 Jul; 43 Suppl 1():82-85. PubMed ID: 34288451
[TBL] [Abstract][Full Text] [Related]
9. Mutations in idiopathic cytopenia of undetermined significance assist diagnostics and correlate to dysplastic changes.
Hansen JW; Westman MK; Sjö LD; Saft L; Kristensen LS; Ørskov AD; Treppendahl M; Andersen MK; Grønbaek K
Am J Hematol; 2016 Dec; 91(12):1234-1238. PubMed ID: 27717004
[TBL] [Abstract][Full Text] [Related]
10. New challenges in evaluating anemia in older persons in the era of molecular testing.
Steensma DP
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):67-73. PubMed ID: 27913464
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of myeloid malignancy‑related somatic mutations in aplastic anemia.
Liu L; Zhang D; Fu Q; Wang J; Yu J; Chen D; Wang F; Guo R; Xie X; Jiang Z; Li Y
Clin Exp Med; 2023 Dec; 23(8):4473-4482. PubMed ID: 37087521
[TBL] [Abstract][Full Text] [Related]
12. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.
Malcovati L; Papaemmanuil E; Ambaglio I; Elena C; Gallì A; Della Porta MG; Travaglino E; Pietra D; Pascutto C; Ubezio M; Bono E; Da Vià MC; Brisci A; Bruno F; Cremonesi L; Ferrari M; Boveri E; Invernizzi R; Campbell PJ; Cazzola M
Blood; 2014 Aug; 124(9):1513-21. PubMed ID: 24970933
[TBL] [Abstract][Full Text] [Related]
13. Clinical and Pathologic Spectrum of DDX41-Mutated Hematolymphoid Neoplasms.
Goyal T; Tu ZJ; Wang Z; Cook JR
Am J Clin Pathol; 2021 Oct; 156(5):829-838. PubMed ID: 33929502
[TBL] [Abstract][Full Text] [Related]
14. The Application of NextGen Sequencing in the Diagnosis of Myeloid Neoplasms in Myeloma Patients With Cytopenia.
Song J; Zhang H; Dong N; Zhang X; Hussaini M; Jain A; Moscinski L; Shain K; Baz R; Alsina M; Nishihori T; Zhang L
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):e414-e426. PubMed ID: 34998786
[TBL] [Abstract][Full Text] [Related]
15. Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies.
Stengel A; Baer C; Walter W; Meggendorfer M; Kern W; Haferlach T; Haferlach C
Blood Adv; 2021 Nov; 5(21):4426-4434. PubMed ID: 34570179
[TBL] [Abstract][Full Text] [Related]
16. Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.
Fernandez-Mercado M; Burns A; Pellagatti A; Giagounidis A; Germing U; Agirre X; Prosper F; Aul C; Killick S; Wainscoat JS; Schuh A; Boultwood J
Haematologica; 2013 Dec; 98(12):1856-64. PubMed ID: 23831921
[TBL] [Abstract][Full Text] [Related]
17. ASXL1 is a molecular predictor in idiopathic cytopenia of undetermined significance.
Shin DY; Park JK; Kim SM; Im K; Kim JA; Kim SY; Hwang SM; Yoon SS; Lee DS
Leuk Lymphoma; 2019 Mar; 60(3):756-763. PubMed ID: 30301403
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and clinical expression of germ line predisposition to myeloid neoplasms in adults with marrow hypocellularity.
Molteni E; Bono E; Gallì A; Elena C; Ferrari J; Fiorelli N; Pozzi S; Ferretti VV; Sarchi M; Rizzo E; Camilotto V; Boveri E; Cazzola M; Malcovati L
Blood; 2023 Aug; 142(7):643-657. PubMed ID: 37216690
[TBL] [Abstract][Full Text] [Related]
19. High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21.
Preudhomme C; Warot-Loze D; Roumier C; Grardel-Duflos N; Garand R; Lai JL; Dastugue N; Macintyre E; Denis C; Bauters F; Kerckaert JP; Cosson A; Fenaux P
Blood; 2000 Oct; 96(8):2862-9. PubMed ID: 11023523
[TBL] [Abstract][Full Text] [Related]
20. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.
Rocquain J; Carbuccia N; Trouplin V; Raynaud S; Murati A; Nezri M; Tadrist Z; Olschwang S; Vey N; Birnbaum D; Gelsi-Boyer V; Mozziconacci MJ
BMC Cancer; 2010 Aug; 10():401. PubMed ID: 20678218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]